In 2015, the release of the EMPA-REG outcome trial demonstrated for the first time that a glucose-lowering agent, empagliflozin, an SGLT2 inhibitor, reduced cardiovascular mortality and heart failure hospitalization when given on top of standard care to patients with T2DM with CVD [6]. The gene discussed is SLC5A2; the disease is heart failure.